A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer.

Autor:	Nguyen VP; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California., Campbell KM; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California., Nowicki TS; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.; Parker Institute for Cancer Immunotherapy, San Francisco, California.; Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of California, Los Angeles, Los Angeles, California.; Department of Microbiology, Immunology and Genetics, University of California, Los Angeles, Los Angeles, California., Elumalai N; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California., Medina E; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California., Baselga-Carretero I; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California., DiNome ML; Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California., Chang HR; Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California., Oseguera DK; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California., Ribas A; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.; Department of Microbiology, Immunology and Genetics, University of California, Los Angeles, Los Angeles, California.; Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California.; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California., Glaspy JA; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.
Jazyk:	angličtina
Zdroj:	Cancer research communications [Cancer Res Commun] 2023 Aug 23; Vol. 3 (8), pp. 1628-1637. Date of Electronic Publication: 2023 Aug 23 (Print Publication: 2023).
DOI:	10.1158/2767-9764.CRC-23-0145
Abstrakt:	Purpose: Neoadjuvant combination immune checkpoint blockade and intralesional oncolytic virotherapy have the potential to activate antitumor responses in patients with breast cancer. Experimental Design: Eligibility for this pilot phase I trial included patients with localized HER2-negative breast cancer who received systemic nivolumab and ipilimumab and intratumor talimogene laherparepvec (T-VEC; NCT04185311). The primary objective was to evaluate the safety and adverse event profile of immunotherapy combined with T-VEC in patients with localized, HER2-negative breast cancer. Results: Six patients were enrolled, 4 having relapses after prior neoadjuvant chemotherapy and 2 who were previously untreated. Toxicities included 1 patient having grade 3 hypotension and type 1 diabetes mellitus, 3 patients with hypothyroidism, and all patients having constitutional symptoms known to be associated with the administration of T-VEC. One patient had a pathologic complete response, 3 patients had pathologic partial responses, 1 showed no significant response, and 1 had disease progression. Biopsies demonstrated increased immune cell infiltration in samples from patients who responded to therapy. Conclusions: This triple immunotherapy regimen provided responses in patients with advanced or relapsed HER2-negative breast cancer, at the expense of long-term toxicities. Significance: Systemic immune checkpoint blockade with a programmed death receptor 1 and a CTL antigen-4 blocking antibody, combined with intralesional oncolytic virotherapy, is a chemotherapy-free combination aimed at inducing an antitumor immune response locally and systemic immunity. (© 2023 The Authors; Published by the American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu